Verismo Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Verismo Therapeutics's estimated annual revenue is currently $2.4M per year.
- Verismo Therapeutics's estimated revenue per employee is $85,804
- Verismo Therapeutics's total funding is $50M.
Employee Data
- Verismo Therapeutics has 28 Employees.
- Verismo Therapeutics grew their employee count by 27% last year.
Verismo Therapeutics's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO / co-founder | Reveal Email/Phone |
2 | Chief Scientific Officer | Reveal Email/Phone |
3 | Quality Lead/ Chief Staff | Reveal Email/Phone |
4 | VP Clinical Operations | Reveal Email/Phone |
5 | VP, Clinical Operations | Reveal Email/Phone |
6 | Head Quality and Compliance | Reveal Email/Phone |
7 | Director, MSAT | Reveal Email/Phone |
8 | Director Corporate Development / Start-Up Member | Reveal Email/Phone |
9 | Senior Director, Translational Science | Reveal Email/Phone |
10 | Senior Manager, Program Management | Reveal Email/Phone |
Verismo Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $1.6M | 7 | -12% | N/A | N/A |
#2 | $4M | 38 | 81% | N/A | N/A |
#3 | N/A | 76 | 27% | N/A | N/A |
#4 | $0.9M | 5 | 0% | N/A | N/A |
#5 | $1.1M | 8 | 33% | N/A | N/A |
#6 | $10.9M | 61 | 7% | N/A | N/A |
#7 | $0.7M | 9 | 29% | N/A | N/A |
#8 | $4M | 20 | -5% | N/A | N/A |
#9 | $1.7M | 11 | 22% | N/A | N/A |
#10 | $7.6M | 49 | 2% | N/A | N/A |
What Is Verismo Therapeutics?
Verismo Therapeutics is pioneering the development of novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer, especially non-hematologic malignancies with few effective therapeutic options. Verismo Therapeutic’s core technology is built upon CARs that are uniquely engineered to more realistically reflect the natural multichain design of killer immunoglobulin-like receptors (KIRs), an important family of immunologic receptors used by T cells and NK cells. Preclinical studies show that SynKIR™-T cells, created by introducing these KIR-based CARs (KIR-CARs) into T cells, more effectively eliminate aggressive tumors in vivo when compared with T cells bearing traditional 2nd generation CAR designs found in current FDA approved CAR-T cell therapies.
keywords:N/A$50M
Total Funding
28
Number of Employees
$2.4M
Revenue (est)
27%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $2.7M | 28 | N/A | N/A |
#2 | $7.5M | 28 | 4% | N/A |
#3 | $2.8M | 28 | -10% | N/A |
#4 | N/A | 28 | 40% | N/A |
#5 | $4.9M | 28 | -15% | N/A |